Unique ID issued by UMIN | UMIN000009622 |
---|---|
Receipt number | R000003874 |
Scientific Title | Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma |
Date of disclosure of the study information | 2012/12/25 |
Last modified on | 2012/12/25 14:56:07 |
Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma
Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of metastatic renal cell carcinoma
Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma
Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of metastatic renal cell carcinoma
Japan |
renal cell carcinoma
Urology |
Malignancy
NO
Exploration of novel biomarkers for response to Sunitinib therapy in the treatment of metastatic renal cell carcinoma in Japanese patients
Efficacy
Confirmatory
inflammation markers
IL-6, CRP, IL-8, hepcidin
immunologic markers
Th1/Th2 bias, TReg, MDSC
angiogenesis markers
VEGF-C, soluble VEGFR-2, soluble VEGFR-3, b-FGF
response rate, progression free survival, overall survival, safety
Observational
18 | years-old | <= |
Not applicable |
Male and Female
1.Japanese patients older than 18.
2.Diagnosed as metastatic renal cell carcinoma with clear cell component.
3.No chemotherapy/radiation has been performed/ or No efficacy by cytokine treatment
4.Having evaluable disease by CT scan, which is regulated in RECIST.
5. Performance status (ECOG) 0-1
6. Maintaining vital organ functions
7. Survival period is expected more than 12 weeks
8. Informed consent has been obtained
1.brain metastasis
2.uncontrollable hypertention
3.Active or symptomatic angina pectoris or coronary artery disease (myocardial infarction within 12 months or symptomatic unstable angina), Symptomatic congestive heart failure, Long QTc
4.History of being allergic to Sunitinib
5.Pregnant or lactating woman, including the possibility of pregnant
6.Post organ transplantation, including hematopoietic stem cell transplantation
7.History of malignancy, excluding following cases
Cervical cancer (carcinoma in situ), Basal cell carcinoma, Superficial bladder cancer(Ta, Tis and T1, which have been treated properly
Malignancies treated radically more than 3 years before, without recurrence
8.History of VEGF/ VEGF-R targeted therapy
9.Systemic treatment with steroids
10.Interstitial pneumonia
70
1st name | |
Middle name | |
Last name | Mototsugu Oya |
Keio University School of Medicine
Department of Urology
35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan
03-5363-3825
1st name | |
Middle name | |
Last name | Ryuichi Mizuno |
Keio University School of Medicine
Department of Urology
35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan
03-5363-3825
mizunor@z7.keio.jp
Tokyo metropolitan Sutent study group
none
Self funding
NO
慶應義塾大学病院、日本医科大学付属病院、東京慈恵会医科大学付属病院、東京慈恵会医科大学付属柏病院、杏林大学医学部付属病院、東京女子医科大学付属病院、埼玉医科大学付属病院、川崎市立川崎病院、
2012 | Year | 12 | Month | 25 | Day |
Unpublished
Completed
2009 | Year | 08 | Month | 28 | Day |
2009 | Year | 11 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
Changes in biomarkers for response to Sunitinib therapy
2012 | Year | 12 | Month | 25 | Day |
2012 | Year | 12 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003874
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |